课题基金 / 基金详情

项目摘要

项目成果

Frederic Barr的其他基金

相似基金

相关文献

中文摘要
翻译
我们最初的目标是开发细胞培养系统,其中PAX 3-FOXO 1表达可以被诱导,并且其中PAX 3-FOXO 1的下游效应可以在基因表达和表型水平上进行评估。为了在计划的研究中测量PAX 3-FOXO 1表达,在RMS细胞系的蛋白质印迹研究中成功地使用针对FOXO 1 C末端的单克隆抗体来检测野生型FOXO 1和/或融合蛋白的表达。类似地验证定量RT-PCR测定用于检测野生型FOXO 1和PAX 3-FOXO 1(或PAX 7-FOXO 1)mRNA。为了在我们计划的研究中产生诱导型表达,肿瘤内科分支的Ji Luo博士提供了四环素诱导型慢病毒表达载体。我们将PAX 3-FOXO 1 cDNA亚克隆到该表达载体中,并将该PAX 3-FOXO 1表达构建体转导到几种细胞系中。为了验证这种诱导型构建体的效用,我们首先将这种构建体转导到鼠NIH 3 T3成纤维细胞中,并在剂量反应研究中观察到PAX 3-FOXO 1 mRNA和蛋白的诱导型增加。PAX 3-FOXO 1蛋白的诱导水平达到与融合阳性RMS细胞中存在的高融合表达水平相当甚至更高的水平。基于我们在NIH 3 T3细胞中产生诱导型PAX 3-FOXO 1表达的初步成功,我们随后将该构建体引入永生化的人Dbt成肌细胞系中。使用我们的蛋白质印迹和RT-PCR测定,我们发现PAX 3-FOXO 1在转导的Dbt细胞中的诱导表达,从未诱导状态下的接近不可检测的水平到反映融合阳性RMS细胞中的高水平的高水平。进一步使用针对FGFR 4和ABAT(两种下游PAX 3-FOXO 1靶标)的qRT-PCR测定揭示了这两种基因表达的诱导性增加。然后,我们进行了PAX 3-FOXO 1在这些转导的Dbt细胞中的表型效应的几种细胞培养测定。与我们先前发表的组成型PAX 3-FOXO 1表达构建体的研究类似,我们分析了具有和不具有组成型MYCN表达的细胞中的表型效应。诱导的PAX 3-FOXO 1表达的毒性作用通过发现当PAX 3-FOXO 1表达被多西环素诱导时这些细胞很少或没有生长而得到证实,这与在没有多西环素的情况下这些细胞的快速生长形成对比。在存在或不存在外源性MYCN表达的情况下观察到这些毒性作用。尽管有这些毒性作用,但具有诱导的PAX 3-FOXO 1表达(以及外源性组成型MYCN表达)的细胞表现出高水平的病灶形成,这是细胞培养物中致癌转化的量度。与没有强力霉素诱导的细胞类似,具有诱导的PAX 3-FOXO 1但没有外源性MYCN表达的细胞没有表现出致癌转化的证据。为了将这些发现扩展到体内环境,已向机构动物护理和使用委员会提交了动物方案,以评估PAX 3-FOXO 1(有或没有MYCN)在促进和维持实验室动物致瘤性方面的作用。
英文摘要
Our initial goal was to develop cell culture systems in which PAX3-FOXO1 expression can be induced and in which the downstream effects of PAX3-FOXO1 can then be assessed at the gene expression and phenotypic levels. To measure PAX3-FOXO1 expression in the planned studies, a monoclonal antibody to the FOXO1 C-terminus was successfully used in western blot studies of RMS cell lines to detect expression of the wild-type FOXO1 and/or fusion protein. Quantitative RT-PCR assays were similarly validated for detection of the wild-type FOXO1 and PAX3-FOXO1 (or PAX7-FOXO1) mRNA's. To generate inducible expression in our planned studies, a tetracycline-inducible lentiviral expression vector was provided by Dr. Ji Luo of the Medical Oncology Branch. We subcloned the PAX3-FOXO1 cDNA into this expression vector and transduced this PAX3-FOXO1 expression construct into several cell lines. To validate the utility of this inducible construct, we first transduced this construct into murine NIH3T3 fibroblast cells and observed inducible increases in PAX3-FOXO1 mRNA and protein in dose-response studies. The induced level of PAX3-FOXO1 protein reached levels equivalent to and even greater than the high fusion expression level present in fusion-positive RMS cells. Based on our initial success in generating inducible PAX3-FOXO1 expression in NIH3T3 cells, we then introduced this construct into the immortalized human Dbt myoblast cell line. Using our western blot and RT-PCR assays, we found inducible expression of PAX3-FOXO1 in the transduced Dbt cells, from near undetectable levels in the uninduced state to high levels that mirror the high levels in fusion-positive RMS cells. Further use of qRT-PCR assays for FGFR4 and ABAT, two downstream PAX3-FOXO1 targets, revealed inducible increases in expression of both of these genes. We then proceeded with several cell culture assays of the phenotypic effects of PAX3-FOXO1 in these transduced Dbt cells. Similar to our previous published studies of constitutive PAX3-FOXO1 expression constructs, we analyzed phenotypic effects in cells with and without constitutive MYCN expression. The toxic effects of induced PAX3-FOXO1 expression were manifest by the finding of little or no growth of these cells when PAX3-FOXO1 expression was induced by doxycycline in contrast to the brisk growth of these cells in the absence of doxycycline. These toxic effects were seen in the presence or absence of exogenous MYCN expression. Despite these toxic effects, the cells with induced PAX3-FOXO1 expression (as well as exogenous constitutive MYCN expression) demonstrated a high level of focus formation, which is a measure of oncogenic transformation in cell culture. Similar to the cells without doxycycline induction, the cells with induced PAX3-FOXO1 but without exogenous MYCN expression did not demonstrate evidence of oncogenic transformation. To extend these findings to the in vivo setting, an animal protocol has been submitted to the Institutional Animal Care and Use Committee to assess the role of PAX3-FOXO1 (with or without MYCN) in contributing to and maintaining tumorigenicity in laboratory animals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies of gene fusions in rhabdomyosarcoma
  • 批准号:
    10486830
  • 项目类别:
  • 资助金额:
    $70.45万
  • 财政年份:
    --
  • 负责人:
    Frederic Barr
  • 依托单位:
Studies of amplification in rhabdomyosarcoma
Studies of gene fusions in rhabdomyosarcoma
Clinical Operations for Laboratory of Pathology
海外基金